News Releases & Research Results Development of a novel antibody drug for canine lymphoma - Starting a veterinarian-initiated clinical trial on canine lymphoma -

The results of collaborative research and development conducted by Professor Takuya Mizuno of the Joint Faculty of Veterinary Medicine, Yamaguchi University; Professor Yukinari Kato of the New Industry Creation Hatchery Center/Graduate School of Medicine, Tohoku University; and Nippon Zenyaku Kogyo Co., Ltd.

• An anti-canine CD20(*) antibody with potent antitumor effects on canine B-cell lymphoma was successfully developed.
  *A molecule found on the surfaces of B lymphocytes, a type of leukocyte. It also exists in normal canine B lymphocytes and lymphoma cells of canine B and some T cell lines.
• This veterinarian-initiated clinical trial on the canine CD20 antibody drug was conducted for the first time in the world at the Joint Faculty of Veterinary Medicine, Yamaguchi University.

This R&D was conducted with the support of the Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS) by AMED.

The results of R&D were published in the American scientific journal Scientific Reports on July 10.

Mizuno T., et al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment Scientific Reports
DOI：10.1038/s41598-020-68470-9